The success of PDE5 inhibitors, blocking hydrolysis of cGMP, and currently used for the treatment of erectile dysfunction stimulated significant interest in other therapeutic applications of the NO/cGMP-dependent signaling pathway. The gene discussed is PDE5A; the disease is erectile dysfunction.